PURPOSE: We aimed to evaluate 4Kscore® and ExosomeDx™ with multiparametric magnetic resonance imaging in the detection of high grade prostate cancer and number of biopsies avoided. MATERIAL AND METHODS: Patients had 1 liquid biomarker test with or without multiparametric magnetic resonance imaging. High grade prostate cancer was defined as Gleason grade group 2 or greater. The overall number of avoided biopsies (with Gleason grade 1 or less), and number of missed Gleason grade 2 or greater cancer among the biopsied patients, were determined. RESULTS: Of the 783 patients in the overall cohort 419 (53.5%) underwent biopsy. 4Kscore and ExosomeDx scores higher than the manufacturers' cut point were associated with PI-RADS™ scores 3 to 5 and Gleason grade 2 or greater prostate cancer. Limiting biopsy to the men with liquid biomarker scores above the manufacturers' cut point would have resulted avoiding 29.5% to 39.9% unnecessary biopsies overall, while missing 4.0% to 4.8% Gleason grade 2 or greater prostate cancer in the biopsy group. Screening algorithms with up-front liquid biomarker testing followed by multiparametric magnetic resonance imaging if the biomarker is above the manufacturers' cut point, then followed by biopsy if the multiparametric magnetic resonance imaging is positive or if 4Kscore 20 or greater or ExosomeDx 19 or greater would have missed 4.8% to 5.6% of Gleason grade 2 or greater prostate cancer in the biopsy group while avoiding 39.4% to 43.0% biopsies and 29.5% to 39.9% multiparametric magnetic resonance imaging overall. Similar algorithms with up-front multiparametric magnetic resonance imaging followed by liquid biomarker testing for negative multiparametric magnetic resonance imaging would have missed 2.4% of Gleason grade 2 or greater prostate cancer in the biopsy group but only avoided 17.2% 19.3% biopsies overall. CONCLUSIONS: Screening algorithms with up-front liquid biomarker testing followed by multiparametric magnetic resonance imaging and biopsy at certain biomarker thresholds could reduce unnecessary biopsies, multiparametric magnetic resonance imaging and overdetection of Gleason grade 1 prostate cancer.
PURPOSE: We aimed to evaluate 4Kscore® and ExosomeDx™ with multiparametric magnetic resonance imaging in the detection of high grade prostate cancer and number of biopsies avoided. MATERIAL AND METHODS:Patients had 1 liquid biomarker test with or without multiparametric magnetic resonance imaging. High grade prostate cancer was defined as Gleason grade group 2 or greater. The overall number of avoided biopsies (with Gleason grade 1 or less), and number of missed Gleason grade 2 or greater cancer among the biopsied patients, were determined. RESULTS: Of the 783 patients in the overall cohort 419 (53.5%) underwent biopsy. 4Kscore and ExosomeDx scores higher than the manufacturers' cut point were associated with PI-RADS™ scores 3 to 5 and Gleason grade 2 or greater prostate cancer. Limiting biopsy to the men with liquid biomarker scores above the manufacturers' cut point would have resulted avoiding 29.5% to 39.9% unnecessary biopsies overall, while missing 4.0% to 4.8% Gleason grade 2 or greater prostate cancer in the biopsy group. Screening algorithms with up-front liquid biomarker testing followed by multiparametric magnetic resonance imaging if the biomarker is above the manufacturers' cut point, then followed by biopsy if the multiparametric magnetic resonance imaging is positive or if 4Kscore 20 or greater or ExosomeDx 19 or greater would have missed 4.8% to 5.6% of Gleason grade 2 or greater prostate cancer in the biopsy group while avoiding 39.4% to 43.0% biopsies and 29.5% to 39.9% multiparametric magnetic resonance imaging overall. Similar algorithms with up-front multiparametric magnetic resonance imaging followed by liquid biomarker testing for negative multiparametric magnetic resonance imaging would have missed 2.4% of Gleason grade 2 or greater prostate cancer in the biopsy group but only avoided 17.2% 19.3% biopsies overall. CONCLUSIONS: Screening algorithms with up-front liquid biomarker testing followed by multiparametric magnetic resonance imaging and biopsy at certain biomarker thresholds could reduce unnecessary biopsies, multiparametric magnetic resonance imaging and overdetection of Gleason grade 1 prostate cancer.
Entities:
Keywords:
biomarkers; biopsy; early detection of cancer; magnetic resonance imaging; prostatic neoplasms
Authors: Massimo Lazzeri; Vittorio Fasulo; Giovanni Lughezzani; Alessio Benetti; Giulia Soldà; Rosanna Asselta; Ilaria De Simone; Marco Paciotti; Pier Paolo Avolio; Roberto Contieri; Cesare Saitta; Alberto Saita; Rodolfo Hurle; Giorgio Guazzoni; Nicolò Maria Buffi; Paolo Casale Journal: Front Oncol Date: 2022-09-06 Impact factor: 5.738
Authors: Leonardo D Borregales; Gina DeMeo; Xiangmei Gu; Emily Cheng; Vanessa Dudley; Edward M Schaeffer; Himanshu Nagar; Sigrid Carlsson; Andrew Vickers; Jim C Hu Journal: J Natl Cancer Inst Date: 2022-07-11 Impact factor: 11.816
Authors: Juan Javier-DesLoges; Amirali Salmasi; Christina Am Jamieson; Jennifer T Anger Journal: J Natl Cancer Inst Date: 2022-08-08 Impact factor: 11.816
Authors: Matthew Parsons; Zoya Sandhu; Bridget Foy; Ernest Chan; Bryan Crawford; Libby Petersen; Benjamin Romney; Daniel Sommers; Jay Bishoff; Steven Lynch; Logan Mclean; David Gill Journal: Front Oncol Date: 2022-05-27 Impact factor: 5.738
Authors: Stefano Salciccia; Anna Laura Capriotti; Aldo Laganà; Stefano Fais; Mariantonia Logozzi; Ettore De Berardinis; Gian Maria Busetto; Giovanni Battista Di Pierro; Gian Piero Ricciuti; Francesco Del Giudice; Alessandro Sciarra; Peter R Carroll; Matthew R Cooperberg; Beatrice Sciarra; Martina Maggi Journal: Int J Mol Sci Date: 2021-04-22 Impact factor: 5.923
Authors: Martina Maggi; Francesco Del Giudice; Ugo G Falagario; Andrea Cocci; Giorgio Ivan Russo; Marina Di Mauro; Giuseppe Salvatore Sepe; Fabio Galasso; Rosario Leonardi; Gabriele Iacona; Peter R Carroll; Matthew R Cooperberg; Angelo Porreca; Matteo Ferro; Giuseppe Lucarelli; Daniela Terracciano; Luigi Cormio; Giuseppe Carrieri; Ettore De Berardinis; Alessandro Sciarra; Gian Maria Busetto Journal: Cancers (Basel) Date: 2021-04-23 Impact factor: 6.639